DYN
Dyne Therapeutics, Inc.
$23.83
+0.99 (+4.33%)
At close · Jul 7
Market Cap
$3.40B
Shares
142,824,687
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.83
Open$22.80
Day$22.45–24.27
52W$8.06–25.00
Avg vol 30d2.1M
Short int22.8M · 16.0% float · 14.3d
Short vol85%
Last earningsMay 11, 2026
DataSep 2020–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+31%
above
Price vs 50-day avg
+27%
above
RSI (14)
73
overbought
MACD trend
Positive
52-week position
93%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+40%
trailing
6-month return
+36%
trailing
YTD return
+22%
this year
Relative strength
+29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
3 of 228 funds reported for Jun 30 · net +104 sh shares
Insider flow
Distributing
Net -$38.8M over 90 days · 86% sells
Short interest
Rising
15.97% of float · ▲ +2.4% MoM · 14.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
228 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
EPS growth
−3%
Y/Y
Free cash flow
$-405.1M
Balance sheet
$744.4M
net cash
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 10, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+31%
Bullish
Price vs 50-day avg
+27%
Bullish
RSI (14)
73
Bearish
MACD trend
Positive
Bullish
52-week position
93%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $19 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
3 of 228 funds reported for Jun 30 · net +104 sh shares
Insider flow
Distributing
Net -$38.8M over 90 days · 86% sells
Short interest
Rising
15.97% of float · ▲ +2.4% MoM · 14.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
228 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $8
Now $24 · 93%
52-wk high $25
vs 200-day avg +31%
vs 50-day avg +27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DYN
this stock
Dyne Therapeutics, Inc.
|
$3.40B | +21.8% | — | — | 16.0% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DYN | +12.1% | +39.9% | +36.5% | +7.3% | +21.8% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +11.2% | +38.5% | +28.9% | +7.2% | +12.2% |